Catching you up on the week of May 11–17, 2026: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Reunion Neuroscience: Reunion to present full RECONNECT Phase 2 data for luvesilocin in postpartum depression
Reunion Neuroscience said it will present full data from its RECONNECT Phase 2 trial of luvesilocin (RE104) in moderate-to-severe postpartum depression at the ASCP and APA annual meetings. The trial met its primary endpoint with a statistically significant MADRS reduction at Day 7, and the FDA granted the candidate Breakthrough Therapy designation in February 2026. Reunion said it expects a single successful Phase 3 trial could complete the data package to support registration in postpartum depression.
Source: globenewswire.com
AtaiBeckley Inc. (ATAI): AtaiBeckley reports Q1 2026 results, cash runway into 2029
AtaiBeckley reported a first-quarter net loss of about $29.8 million and a loss of $0.08 per share, with roughly $954,000 in revenue, ahead of some analyst expectations. Cash, equivalents and short-term securities stood at $209.9 million as of March 31, which the company said funds operations into 2029. It reiterated that its BPL-003 (5-MeO-DMT) program is on track to begin a Phase 3 pivotal program in Q2 2026, with VLS-01 Phase 2 topline data expected in Q4 2026.
Source: globenewswire.com
Clearmind Medicine Inc. (CMND): Clearmind reaches 20 patients dosed in CMND-100 alcohol use disorder trial
Clearmind Medicine said two more patients were dosed in the fourth cohort of its FDA-cleared Phase 1/2a trial of CMND-100 (MEAI) for moderate-to-severe alcohol use disorder, bringing the total treated to 20 across all cohorts. The fourth cohort uses a higher 160 mg dose following a positive safety-monitoring-board recommendation, and the newest patients were treated at Hadassah Medical Center in Jerusalem. The update marks steady enrollment progress for the microcap's lead non-hallucinogenic program.
Source: globenewswire.com
Compass Pathways plc (CMPS): Compass reports Q1 2026 results with $466 million cash position
Compass Pathways reported first-quarter 2026 results, posting a loss of roughly $0.30 per share and cash and equivalents of about $466 million against $50.5 million of debt as of March 31. Management reaffirmed that its cash position funds operations into 2028. The update followed the FDA's grant of rolling review and a National Priority Voucher for COMP360, keeping the company on track toward a Q4 2026 NDA submission.
Source: businesswire.com
GH Research PLC (GHRS): GH Research reports Q1 2026 results and progress toward GH001 Phase 3
GH Research reported a first-quarter 2026 loss of about $0.31 per share and cash, equivalents and marketable securities of $267.3 million as of March 31. The company said it completed enrollment in its GH001-HV-106 clinical pharmacology trial and selected doses for its planned global Phase 3 pivotal program of inhaled mebufotenin (GH001) in treatment-resistant depression. GH Research said it is seeking FDA alignment while continuing to target Phase 3 initiation.
Source: investor.ghres.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.